No Data
Beijing Wantai Biological Pharmacy Enterprise (603392.SH): Application for clinical trial of nine-valent HPV vaccine in males has received the drug clinical trial approval letter.
Gelonghui reported on November 18 that Beijing Wantai Biological Pharmacy Enterprise (603392.SH) announced that its wholly owned subsidiary, Xiamen Wantai Canghai Biotechnology Co., Ltd., received a "Clinical Trial Notification" issued by the National Medical Products Administration, agreeing to conduct clinical trials for the nine-valent human papillomavirus vaccine (Escherichia coli) (referred to as the "nine-valent HPV vaccine") for indications in the male population.
Beijing Wantai Biological Pharmacy Enterprise (603392.SH): The company currently has no plans to produce the non-segmented HPV vaccine.
Gelonghui November 7th | Beijing Wantai Biological Pharmacy Enterprise (603392.SH) stated on the interactive platform that the company has no plans for segmented production of the nine-valent HPV vaccine.
Beijing Wantai Biological Pharmacy Enterprise (603392.SH): The second-phase expansion project of the nine-valent cervical cancer vaccine is progressing as planned, with the main equipment procurement and workshop purification renovation completed.
Gelonghui November 7th | Beijing Wantai Biological Pharmacy Enterprise (603392.SH) stated on the interactive platform that the Phase II expansion project of the nine-valent cervical cancer vaccine is progressing as planned. The main equipment procurement and workshop purification renovation have been completed, and equipment commissioning and validation are underway. In addition to the flagship product, the nine-valent HPV vaccine, other research and development projects of the company are progressing orderly.
Wantai Biotech 2024 Third Quarter Report
IVD sector growth cannot hide the decline in performance. Q0.03 million Tai Biological net profit plummeted more than 90%. | Interpretations
①Affected by market adjustments, government centralized procurement, etc., beijing wantai biological pharmacy enterprise's biological vaccine sector continues to drag down the company's performance. ② The company's diagnostic sector business has grown, and the chemiluminescence product line maintained rapid double-digit growth compared to the same period last year. ③ With factors such as increased investment in industrialization of the nine-valent HPV vaccine, beijing wantai biological pharmacy enterprise's revenue and net profit attributable to the parent company decreased significantly in the first three quarters.
Beijing Wantai Biological Pharmacy Enterprise (603392.SH): The net income for the first three quarters was 0.267 billion yuan, a year-on-year decrease of 85.25%.
Gelonghui October 24th | Beijing Wantai Biological Pharmacy Enterprise (603392.SH) released the third quarter report of 2024, with the company's revenue in the first three quarters of 1.948 billion yuan, a year-on-year decrease of 60.79%; the net income attributable to shareholders of the listed company was 0.267 billion yuan, a year-on-year decrease of 85.25%; the net income excluding non-recurring gains and losses attributable to shareholders of the listed company was 40.996 million yuan, a year-on-year decrease of 97.55%; basic earnings per share was 0.21 yuan.
102884128 : getting disappointed with this counter. every day drop.